+ 33 1 46 99 68 20
Laboratoires Delbert signs the Supplier Relations and Purchasing Charter

Laboratoires Delbert signs the Supplier Relations and Purchasing Charter

Laboratoires Delbert is pleased to announce that it has signed the Responsible Purchasing and Supplier Relations (RFAR) charter.

 

Committed since its creation to responsible approaches with its suppliers, on January 23, 2023 Laboratoires Delbert formalized these commitments by becoming a signatory to the “Responsible Supplier Relations and Purchasing” Charter steered by the Médiateur des Entreprises and the CNA (Conseil National des Achats).

This approach is part of Laboratoires Delbert’s ongoing efforts to integrate environmental and social priorities into its activities. Through this document, Laboratoires Delbert commits to 10 principles for responsible purchasing.

 

10 COMMITMENTS TO RESPONSIBLE PURCHASING

01.

Ensure a responsible financial relationship with suppliers.

02.

Maintain a respectful relationship with all suppliers, favoring the development of collaborative relationships.

03.

Identify and manage reciprocal dependencies with suppliers.

04.

Involve signatory organizations in their industry.

05.

Appreciate all life-cycle costs and impacts.

06.

Integrate environmental and social responsibility issues.

07.

Ensure the territorial responsibility of its organization.

08.

The professionalism and ethics of the purchasing function.

09.

A Purchasing function responsible for overall management of supplier relations.

10.

A “supplier relations” mediator to smooth internal and external relations.

Article Le Monde: Delbert, saving essential medicines from dissapearing

Article Le Monde: Delbert, saving essential medicines from dissapearing

Article published on Lemonde.fr, December 2, 2022.

Since 2013, the pharmaceutical company has been fighting to breathe new life into essential old molecules threatened with disappearing from the therapeutic arsenal. With each new dossier that lands on its desk, the rule is always the same.

“We check that the medicine meets a clear medical need, then assess whether its development is technically feasible in France or Europe. If we’re 85% sure, we go ahead”, explains Thierry Hoffmann, Managing Director of Laboratoires Delbert.

READ MORE on lemonde.fr